Priscilla F McAuliffe
Overview
Explore the profile of Priscilla F McAuliffe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
911
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bender C, Sereika S, Gentry A, Zhu Y, Wagner M, Cuglewski C, et al.
Support Care Cancer
. 2025 Mar;
33(3):244.
PMID: 40035875
Purpose: Women receiving aromatase inhibitors (AIs) for breast cancer frequently experience musculoskeletal symptoms (AIMS) including joint pain, stiffness, and muscle weakness. Aerobic exercise may reduce AIMS, but the evidence is...
2.
Chang A, Schlegel B, Carleton N, McAuliffe P, Oesterreich S, Schwartz R, et al.
bioRxiv
. 2025 Mar;
PMID: 40027773
Spatial transcriptomics provides insights into tissue architecture by linking gene expression with spatial localization. Current deconvolution methods rely heavily on single-cell RNA sequencing (scRNA-seq) references, which are costly and often...
3.
Nakhlis F, Baker G, Li T, McAuliffe P, Plitas G, Ludwig K, et al.
Ann Surg Oncol
. 2025 Jan;
32(4):2608-2609.
PMID: 39871076
No abstract available.
4.
Sanoba S, Thull D, McAuliffe P, Steiman J, Johnson R, Diego E, et al.
Breast Cancer Res Treat
. 2025 Jan;
209(3):683.
PMID: 39762709
No abstract available.
5.
Nakhlis F, Baker G, Li T, McAuliffe P, Plitas G, Ludwig K, et al.
Ann Surg Oncol
. 2025 Jan;
32(4):2578-2584.
PMID: 39751983
Background: Flat epithelial atypia (FEA), a rare breast proliferative lesion, is often diagnosed following core biopsy (CB) of mammographic microcalcifications. In the prospective multi-institution TBCRC 034 trial, we investigate the...
6.
Zuley M, Bandos A, Duffy S, Logue D, Bhargava R, McAuliffe P, et al.
J Clin Oncol
. 2024 Dec;
43(7):896-897.
PMID: 39689268
No abstract available.
7.
Partridge A, Hyslop T, Rosenberg S, Bennett A, Drier S, Jonsson M, et al.
JAMA Oncol
. 2024 Dec;
PMID: 39665588
Importance: Active monitoring (AM) for low-risk ductal carcinoma in situ (DCIS) has been considered as a potential alternative to guideline-concordant care (GCC; inclusive of surgery with or without radiation). Reported...
8.
Hwang E, Hyslop T, Lynch T, Ryser M, Weiss A, Wolf A, et al.
JAMA
. 2024 Dec;
PMID: 39665585
Importance: Active monitoring for low-risk ductal carcinoma in situ (DCIS) of the breast has been proposed as an alternative to guideline-concordant care, but the safety of this approach is unknown....
9.
Panesso-Gomez S, Cole A, Wield A, Anyaeche V, Shah J, Jiang Q, et al.
bioRxiv
. 2024 Nov;
PMID: 39605642
Chemoresistance is a major driver of cancer deaths. One understudied mechanism of chemoresistance is quiescence. We used single cell culture to identify, retrieve, and RNA-Seq profile primary quiescent ovarian cancer...
10.
Carleton N, Lee S, Li R, Zou J, Brown D, Hooda J, et al.
bioRxiv
. 2024 Nov;
PMID: 39484485
Translational Summary: We uncover the unique underpinnings establishing how the systemic host environment contributes to the aged breast tumor microenvironment, characterized by high local estradiol and chronic inflammation with immune...